EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

High‐resolution HLA sequencing and hypocretin receptor 2 autoantibodies in narcolepsy type 1 and type 2

Samia Hamdan, Pontus Wasling, Alexander Lind iD

International Journal of Immunogenetics · 2024

DOI: 10.1111/iji.12688 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Immunogenetics, 2024. Verfasst von Samia Hamdan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences, Malmö, Lund University, Malmo, Sweden. Hauptthemen laut MEDLINE: Narcolepsy, Orexin Receptors, Autoantibodies. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Stiftelsen Sven Jerrings Fond, Gunvor och Josef Anérs Siftelse, Linnéa och Josef Carlssons Stiftelse.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Narcolepsy is a sleep disorder caused by an apparent degeneration of orexin/hypocretin neurons in the lateral hypothalamic area and a subsequent decrease in orexin/hypocretin levels in the cerebrospinal fluid. Narcolepsy is classified into type 1 (NT1) and type 2 (NT2). While genetic associations in the human leukocyte antigen (HLA) region and candidate autoantibodies have been investigated in NT1 to imply an autoimmune origin, less is known about the pathogenesis in NT2. Twenty‐six NT1 and 15 NT2 patients were included, together with control groups of 24 idiopathic hypersomnia (IH) patients and 778 general population participants. High‐resolution sequencing was used to determine the alleles, the extended haplotypes, and the genotypes of HLA‐ DRB3 , ‐DRB4 , ‐DRB5 , ‐DRB1 , ‐DQA1 , ‐DQB1 , ‐DPA1 , and ‐DPB1 . Radiobinding assay was used to determine autoantibodies against hypocretin receptor 2 (anti‐HCRTR2 autoantibodies). NT1 was associated with HLA‐DRB5*01:01:01 , ‐DRB1*15:01:01 , ‐DQA1*01:02:01 , ‐DQB1*06:02:01 , ‐DRB5*01:01:01 , ‐DRB1*15:01:01 , ‐DQA1*01:02:01 , ‐DQB1*06:02:01 (odds ratio [OR]: 9.15; p = 8.31 × 10 −4 ) and HLA‐DRB5*01:01:01 , ‐DRB1*15:01:01 , ‐DQA1*01:02:01 , ‐DQB1*06:02:01 , ‐DRB4*01:03:01 , ‐DRB1*04:01:01 , ‐DQA1*03:02//03:03:01 , ‐DQB1*03:01:01 (OR: 23.61; p = 1.58 × 10 −4 ) genotypes. Lower orexin/hypocretin levels were reported in the NT2 subgroup ( n = 5) that was associated with the extended HLA‐DQB1*06:02:01 haplotype ( p = .001). Anti‐HCRTR2 autoantibody levels were not different between study groups ( p = .8524). We confirmed the previous association of NT1 with HLA‐DQB1*06:02:01 extended genotypes. A subgroup of NT2 patients with intermediate orexin/hypocretin levels and association with HLA‐DQB1*06:02:01 was identified, indicating a possible overlap between the two distinct narcolepsy subtypes, NT1 and NT2. Low anti‐HCRTR2 autoantibody levels suggest that these receptors might not function as autoimmune targets in either NT1 or NT2.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NarcolepsyOrexin ReceptorsAutoantibodiesHumansFemaleMaleAdultMiddle AgedAllelesHaplotypesHLA AntigensGenotypeGenetic Predisposition to DiseaseYoung AdultAdolescent

Stichwörter der Autor:innen

HLA high‐resolution sequencinghypocretin receptor 2 autoantibodiesnarcolepsy type 1narcolepsy type 2

Substanzen

Orexin ReceptorsAutoantibodiesHCRTR2 protein, humanHLA Antigens

Autor:innen und Institutionen

  • Department of Clinical Sciences, Malmö, Lund University, Malmo, Sweden.
  • Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden.

ORCID-Profile: Alexander Lind

Förderung

  • Stiftelsen Sven Jerrings Fond
  • Gunvor och Josef Anérs Siftelse
  • Linnéa och Josef Carlssons Stiftelse
  • Kronprinsessan Lovisas Förening För Barnasjukvård/Stiftelsen Axel Tielmans Minnesfond
  • Rune Ljungdahls Stiftelse
  • Neuro Sweden
  • Stiftelsen till minne av Personalföreningarna i Holmia Försäkring AB
  • Stiftelsen Samariten

Zitieren

APA

Hamdan, S., Wasling, P., & Lind, A. (2024). High‐resolution HLA sequencing and hypocretin receptor 2 autoantibodies in narcolepsy type 1 and type 2. International Journal of Immunogenetics. https://doi.org/10.1111/iji.12688

Vancouver

Hamdan S, Wasling P, Lind A. High‐resolution HLA sequencing and hypocretin receptor 2 autoantibodies in narcolepsy type 1 and type 2. International Journal of Immunogenetics. 2024. doi:10.1111/iji.12688

BibTeX
@article{Hamdan2024,
  author = {Hamdan, Samia and Wasling, Pontus and Lind, Alexander},
  title = {High‐resolution HLA sequencing and hypocretin receptor 2 autoantibodies in narcolepsy type 1 and type 2},
  journal = {International Journal of Immunogenetics},
  year = {2024},
  doi = {10.1111/iji.12688}
}
Kostenlos starten →